Does dexmedetomidine reduce the risk of acute kidney injury after cardiac surgery? A meta-analysis of randomized controlled trials
Brazilian Journal of Anesthesiology (English Edition) · 2024
DOI: 10.1016/j.bjane.2023.07.003 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Brazilian Journal of Anesthesiology (English Edition), 2024. Verfasst von Chunxiao Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Capital Medical University, Beijing Shijitan Hospital, Department of Intensive Care Unit, Beijing, China. Electronic address: 15830171446@163.com. Hauptthemen laut MEDLINE: Acute Kidney Injury, Cardiac Surgical Procedures, Dexmedetomidine, Postoperative Complications. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Acute Kidney Injury (AKI) is a common complication after cardiac surgery and has been associated with poor outcomes. Dexmedetomidine (DEX) has been shown to confer direct renoprotection based on some animal and clinical studies, but data from other trials came to the opposite conclusion following cardiac surgery. This meta-analysis was conducted to evaluate the effects of perioperative DEX administration on the occurrence of AKI and the outcomes after cardiac surgery.
Methods
We searched databases including EMBASE, PubMed, and Cochrane CENTRAL for Randomized Controlled Trials (RCTs) focused on DEX for AKI in adult patients after cardiac surgery. The primary outcome was incidence of AKI. Secondary outcomes were Mechanical Ventilation (MV) duration, Intensive Care Unit (ICU) Length Of Stay (LOS), hospital LOS and mortality.
Results
Fifteen trials enrolling 2907 study patients were collected in the meta-analyses. Compared with controls, DEX reduced the incidence of postoperative AKI (Odds Ratio [OR = 0.66]; 95% Confidence Interval [95% CI 0.48–0.91]; p = 0.01), and there was no significant difference between groups in postoperative mortality (OR = 0.63; 95% CI 0.32–1.26; p = 0.19), MV duration (Weighted Mean Difference [WMD = -0.44]; 95% CI -1.50–0.63; p = 0.42), ICU LOS (WMD = -1.19; 95% CI -2.89-0.51; p = 0.17), and hospital LOS (WMD = -0.31; 95% CI -0.76–0.15; p = 0.19).
Conclusions
Perioperative DEX reduced the incidence of postoperative AKI in adult patients undergoing cardiac surgery. No significant decrease existed in mortality, MV duration, ICU LOS and hospital LOS owing to DEX administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Capital Medical University, Beijing Shijitan Hospital, Department of Intensive Care Unit, Beijing, China. Electronic address: 15830171446@163.com.
- Capital Medical University, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Department of Pharmacy, Beijing, China.
- Capital Medical University, Beijing Shijitan Hospital, Department of Intensive Care Unit, Beijing, China.
Zitieren
APA
Zhao, C., Liu, S., Zhang, H., & Gao, M. (2024). Does dexmedetomidine reduce the risk of acute kidney injury after cardiac surgery? A meta-analysis of randomized controlled trials. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2023.07.003
Vancouver
Zhao C, Liu S, Zhang H, Gao M. Does dexmedetomidine reduce the risk of acute kidney injury after cardiac surgery? A meta-analysis of randomized controlled trials. Brazilian Journal of Anesthesiology (English Edition). 2024. doi:10.1016/j.bjane.2023.07.003
BibTeX
@article{Zhao2024,
author = {Zhao, Chunxiao and Liu, Shuo and Zhang, Huiquan and Gao, Mengqi},
title = {Does dexmedetomidine reduce the risk of acute kidney injury after cardiac surgery? A meta-analysis of randomized controlled trials},
journal = {Brazilian Journal of Anesthesiology (English Edition)},
year = {2024},
doi = {10.1016/j.bjane.2023.07.003}
}
EUVIMED